Telomir Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
TELO$0.57-17.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows (unaudited)
STATEMENTS OF CASH FLOWS
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from Operating activities: | ||
| Net loss | $(990,947) | $(2,179,828) |
| Adjustments to reconcile net loss to net cash used in operations | ||
| Stock-based compensation expense | 39,803 | 1,375,686 |
| Change in operating assets and liabilities: | ||
| Prepaid expenses | (174,335) | (30,315) |
| Trade accounts payable and accrued liabilities | (257,153) | (28,675) |
| Due to related parties | 26,592 | — |
| Accrued compensation - officer | (417,470) | — |
| Net cash used in operating activities | (1,773,510) | (863,132) |
| Cash flows from Financing activities: | ||
| Repayment to officer | (155,518) | — |
| Proceeds from issuance of insurance loan payable | 224,789 | — |
| Repayments on insurance loan payable | (21,920) | — |
| Net cash provided by financing activities | 47,351 | — |
| Net change in cash | (1,726,159) | (863,132) |
| Cash, beginning of period | 7,286,670 | 1,266,131 |
| Cash, end of period | $5,560,511 | $402,999 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $1,255 | $— |
| Cash paid for income tax | $— | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.